Renal cell cancer
Conditions
Interventions
None listed
Sponsors
Graduate School of Medical Sciences, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who were treated or are planned to be treated with nivolumab for advanced renal cancer 2.Patients diagnosed with clear cell carcinoma pathologically 3.Patients with at least one measurable lesion according to RECIST v1.1 criteria 4.Patients who fully understand this research plan and can give their consent 5.Japanese people over 20 years of age at the time of consent acquisition
Exclusion criteria
Exclusion criteria: 1.non-Japanese patients 2.Patients in whom the evaluation of response rate according to RECIST ver.1.1 is not carried out within 24 weeks after the start of treatment 3.Patients who received nivolumab as first line treatment 4.Patients who co-administered with drugs for renal cancer other than nivolumab 5.Patients who are judged inappropriate for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SNPs that correlate with tumor response to nivolumab | — |
Secondary
| Measure | Time frame |
|---|---|
| SNPs that correlate with progression , treatment continuation and overall survival in nivolumab treatment SNPs that correlate with adverse events in nivolumab treatment | — |
Countries
Japan
Contacts
Public ContactMasaki Shiota
Kyushu University Hospital Department of Urology
Outcome results
None listed